Vitamin E reduces liver stiffness in nonalcoholic fatty liver disease

Fukui, Aiko; Kawabe, Naoto; Hashimoto, Senju; Murao, Michihito; Nakano, Takuji; Shimazaki, Hiroaki; Kan, Toshiki; Nakaoka, Kazunori; Ohki, Masashi; Takagawa, Yuka; Takamura, Tomoki; Kamei, Hiroyuki; Yoshioka, Kentaro

doi:10.4254/wjh.v7.i27.2749

Cited by 18 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several limitations of the study, such as the use of hetero geneous diagnosis procedures for NAFLD, variable vitamin E dosing, surrogate assessment of liver fibrosis and retrospective design without controls preclude any strong conclusions. Nevertheless, it seems that vitamin E treatment efficacy is not importantly influenced by PNPLA3 genotype [148].…”

Section: Pharmacogenetics Of Putative Nafld Drugsmentioning

confidence: 96%

“…A recent smallscale study investigated whether PNPLA3 polymorphisms have an influence on vita min E treatment efficacy [148]. Thirtyeight patients with NAFLD received between 150 and 600 mg of vitamin E daily for >1 year as treatments for athero sclerosis, diabetic retinopathy or prevention of lipid peroxidation.…”

Section: Pharmacogenetics Of Putative Nafld Drugsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacogenomic and Personalized Approaches to Tackle Nonalcoholic Fatty Liver Disease

2016

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is a raising liver disease with increasing prevalence due to the epidemics of obesity and diabetes, with end points in cirrhosis or hepatocellular carcinoma. A multitude of genetic and metabolic perturbations, together with environmental factors, likely drive the disease. However, to date only a few genes, primarily PNPLA3 and TM6SF2, associate with NAFLD and there is no specific treatment. In this review we focus on the therapeutical aspects of NAFLD, taking into account drugs and lifestyle interventions. Sex also influences disease progression and treatment outcomes. Lastly, we discuss the present and potential future of personalized approaches to tackle NAFLD and how the known polymorphisms of NAFLD associated genes influence the choice and success of therapy.

show abstract

Section: Pharmacogenetics Of Putative Nafld Drugsmentioning

confidence: 96%

Section: Pharmacogenetics Of Putative Nafld Drugsmentioning

confidence: 99%

Pharmacogenomic and Personalized Approaches to Tackle Nonalcoholic Fatty Liver Disease

2016

View full text Add to dashboard Cite

show abstract

“…Studies assessing the relationship between vitamin E response and PNPLA3 are limited, and there is no data available from the PIVENS/TONIC trial. In a small exploratory study, 38 NAFLD patients received either 150, 300, or 600 mg vitamin E three times a day for one year [ 70 ]. Vitamin E was effective in lowering liver enzymes, non-invasive fibrosis scores (FIB-4 index and aspartate aminotransferase-to-platelet index (APRI)), and liver stiffness.…”

Section: Genetic Factors Associated With Treatment Responsementioning

confidence: 99%

Genetic Factors Associated with Response to Vitamin E Treatment in NAFLD

Civelek

Podszun

2022

Antioxidants

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is becoming the predominant liver disease worldwide, and vitamin E has been clinically shown to improve histological parameters in a subset of patients. In this narrative review, we investigate whether genetic factors may help to explain why some patients show histological improvements upon high-dose alpha-tocopherol (αT) treatment while others do not. In summary, we identified two factors that are associated with treatment response, including genetic variations in haptoglobin as well as fatty acid desaturase 1/2 (FADS1/FADS2). Other genetic variants such as in alpha-tocopherol transfer protein (αTTP), tocopherol associated protein (TAP), transmembrane 6 superfamily 2 (TM6SF2), cluster of differentiation 36 (CD36), and proteins involved in lipoprotein metabolism may also play a role, but have not yet been investigated in a clinical context. We propose to further validate these associations in larger populations, to then use them as a clinical tool to identify the subset of patients that will benefit the most from vitamin E supplementation.

show abstract

“…Gene polymorphism of cytochrome P450 4F2 might affect Vitamin E pharmacokinetics and could determine variability in its efficacy, as demonstrated a study with data from the PIVENS and TONIC clinical trials [117]. However, a retrospective study showed that liver stiffness reduction in patients with NAFLD taking Vitamin E was not influenced by PNPLA3 genotypes [118]. On the other hand, several genetic predictors of response to obeticholic acid in patients with NASH were identified in a pilot GWAS study, with the CELA3B rs75508464 variant with the most significant effect on NASH resolution [119].…”

Section: Other Therapiesmentioning

confidence: 99%

Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease

et al. 2021

View full text Add to dashboard Cite

In the last decades, the global prevalence of non-alcoholic fatty liver disease (NAFLD) has reached pandemic proportions with derived major health and socioeconomic consequences; this tendency is expected to be further aggravated in the coming years. Obesity, insulin resistance/type 2 diabetes mellitus, sedentary lifestyle, increased caloric intake and genetic predisposition constitute the main risk factors associated with the development and progression of the disease. Importantly, the interaction between the inherited genetic background and some unhealthy dietary patterns has been postulated to have an essential role in the pathogenesis of NAFLD. Weight loss through lifestyle modifications is considered the cornerstone of the treatment for NAFLD and the inter-individual variability in the response to some dietary approaches may be conditioned by the presence of different single nucleotide polymorphisms. In this review, we summarize the current evidence on the influence of the association between genetic susceptibility and dietary habits in NAFLD pathophysiology, as well as the role of gene polymorphism in the response to lifestyle interventions and the potential interaction between nutritional genomics and other emerging therapies for NAFLD, such as bariatric surgery and several pharmacologic agents.

show abstract

Vitamin E reduces liver stiffness in nonalcoholic fatty liver disease

Abstract: One year of vitamin E treatment improved noninvasive fibrosis scores and liver stiffness in NAFLD patients. The responses were similar between different PNPLA3 genotypes.

Cited by 18 publications

References 31 publications

Pharmacogenomic and Personalized Approaches to Tackle Nonalcoholic Fatty Liver Disease

Pharmacogenomic and Personalized Approaches to Tackle Nonalcoholic Fatty Liver Disease

Genetic Factors Associated with Response to Vitamin E Treatment in NAFLD

Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease

Contact Info

Product

Resources

About